Shanghai-headquartered biopharmaceutical company Elpiscience Biopharmaceutical has secured $100 million in a Series B round to advance its immunotherapy drug candidates through pre-clinical and clinical stages, per an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
